Geisinger and Fox Chase Cancer Center Strategic Alliance Brings New Cancer Programs to Area Residents
Wilkes-Barre - Geisinger Health System and Fox Chase Cancer Center, Philadelphia, have formed a patient-focused strategic alliance that will provide comprehensive state-of-the-art cancer services and programs for residents in northeastern and central Pennsylvania.
The strategic alliance is part of a significant relationship between Geisinger and Fox Chase Cancer Center that was announced last year. The alliance includes partnering on a new program at The Henry Cancer Center at Geisinger Wyoming Valley Medical Center in Wilkes-Barre. One of the significant achievements of the alliance is the hiring of Mohammed Mohiuddin, MD, FRCR, FACR, who will be joining Geisinger in August to serve as Director of the Geisinger and Fox Chase program in Wilkes-Barre and as Co-Director of the Geisinger Health System Cancer Institute.
Programs included in the strategic alliance are cancer prevention strategies, enhanced diagnostics techniques, and the most up-to-date treatment available, including access to the most advanced research and treatment modalities, clinical trials and innovations.
"Clinical research and the dissemination of research findings for the benefit of patients are key components of our relationship with Fox Chase Cancer Center," said Geisinger President and CEO Glenn D. Steele, Jr., MD, who is Co-Chairman of the Strategic Alliance Advisory Board. "The goal of the Geisinger and Fox Chase Cancer Center strategic alliance is to reduce the cancer burden for people we serve in Pennsylvania. The alliance, our partnership in Wilkes-Barre, and the addition of a physician leader with the exemplary credentials of Dr. Mohiuddin is very good news for the people we serve."
According to Robert C. Young, MD, Fox Chase President and CEO and Strategic Alliance Advisory Board Co-Chairman, physician researchers at both institutions will work closely to develop and expand research opportunities, including clinical trials.
"Clinical trials examine novel approaches to cancer prevention and treatment by testing new drugs or combinations of drugs, radiation, and surgery," Dr. Young explained. "Our alliance allows an enhanced opportunity for our researchers to translate laboratory discoveries-accelerating the time it takes to put a discovery into the hands of physicians to better treat patients."
Examples of research projects in progress include: a population-based study designed to promote colorectal cancer screening in women and another study that compares methods of motivating siblings of colorectal cancer patients to undergo screening.
"Disseminating research findings is an important benefit of the strategic alliance," said Dr. Steele. "Using Geisinger's system-wide secure electronic medical record system, we can integrate treatment guidelines to ensure our patients are getting the most up-to-date, research-based therapies. Geisinger's Center for Healthcare Research and Rural Advocacy will also play a role in communicating findings from the collaborative research."
Geisinger Health System is also a member of Fox Chase Cancer Center's CCOP (Community Clinical Oncology Program) research base for cancer prevention and control initiatives. This National Cancer Institute-sponsored program offers additional opportunities for Geisinger and Fox Chase physicians and researchers to collaborate in cancer control and prevention activities that are currently underway. Dr. Mohiuddin is a specialist in radiation oncology. He joins Geisinger from the University of Kentucky where he served as chairman of radiation medicine. His research interest involves cancers of the rectum, prostate, bladder and pancreas. A fellow of the Royal College of Radiology in London, England, Mohiuddin received his medical degree from Osmania Medical College in Hyderabad, India. He completed his residency at the highly regarded Royal Marsden Hospital in London, England.
Geisinger Health System is an integrated, physician-led health services organization serving more than two million residents throughout central and northeastern Pennsylvania. It includes a tertiary/quaternary medical center with the nation's first rural children's hospital, a secondary community acute-care hospital, adult and pediatric trauma centers, a nationally acclaimed alcohol and chemical dependency treatment center, a heart institute, a cancer institute, a neurosciences program, two research centers, 41 community practice physician offices, and one of the largest not-for-profit rural HMOs in the country. For more information, visit www.geisinger.org.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.